-
Start Preamble
ACTION:
Notice of application.
DATES:
Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before May 8, 2017.
ADDRESSES:
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on November 14, 2016, Mallinckrodt, LLC, 3600 North Second Street, Saint Louis, Missouri 63147 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:
Start Printed Page 13137Controlled substance Drug code Schedule Gamma Hydroxybutyric Acid 2010 I Tetrahydrocannabinols 7370 I Codeine-N-oxide 9053 I Dihydromorphine 9145 I Difenoxin 9168 I Morphine-N-oxide 9307 I Normorphine 9313 I Norlevorphanol 9634 I Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) 9821 I Butyryl Fentanyl 9822 I Amphetamine 1100 II Methamphetamine 1105 II Lisdexamfetamine 1205 II Methylphenidate 1724 II Nabilone 7379 II 4-Anilino-N-phenethyl-4-piperidine (ANPP) 8333 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Diphenoxylate 9170 II Ecgonine 9180 II Hydrocodone 9193 II Levorphanol 9220 II Meperidine 9230 II Methadone 9250 II Methadone intermediate 9254 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Opium tincture 9630 II Opium, powdered 9639 II Oxymorphone 9652 II Noroxymorphone 9668 II Alfentanil 9737 II Remifentanil 9739 II Sufentanil 9740 II Tapentadol 9780 II Fentanyl 9801 II The company plans to manufacture bulk active pharmaceutical ingredients (APIs) for distribution to its customers.
Start SignatureLouis J. Milione,
Assistant Administrator.
[FR Doc. 2017-04645 Filed 3-8-17; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 03/09/2017
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of application.
- Document Number:
- 2017-04645
- Dates:
- Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before May 8, 2017.
- Pages:
- 13136-13137 (2 pages)
- Docket Numbers:
- Docket No. DEA-392
- PDF File:
- 2017-04645.pdf